All News

The Food and Drug Administration has approved its first biosimilar, Zarxio (filgrastim-sndz), for all five of its counterpart Neupogen's authorized indications.

Treating patients with triple-negative breast cancer (TNBC) remains a challenge because these tumors do not rely on hormone receptors or HER2 amplification for tumor growth.

Results of a new study may help more lung cancer patients be eligible to participate in clinical trials.Researchers found that previously having cancer does not impact clinical outcomes in lung cancer patients.

Living in denial is sometimes not such a bad idea, especially when it comes to cancer.

The Food and Drug Administration has approved the anti–PD-1 agent Opdivo (nivolumab) for the treatment of patients with advanced squamous non-small cell lung cancer (NSCLC). The approval comes three months ahead of the FDA's scheduled decision date.

With a growing number of people turning to social media for medical advice, it appears to be more important than ever for physicians to be contributing to the conversation.

Kyprolis doubled progression-free survival versus Velcade in patients with relapsed multiple myeloma in the phase 3 ENDEAVOR trial.

Looking at prior treatment and efficacy data, researchers finds significant benefit with radiotherapy when given to older patients with hormone-negative invasive breast cancer who had undergone breast-conserving surgery.

A detailed tumor profile of molecular and protein alterations in a rare breast cancer subtype called metaplastic breast cancer, was one of the top studies presented at the Miami Breast Cancer Conference this year.

The Food and Drug Administration (FDA) has granted a priority review to Opdivo for use in patients with previously treated, advanced, squamous non-small cell lung cancer (NSCLC). A decision will be made by June 22, 2015.

Now that the big day has arrived, what happens next? It may not be as exciting as advertised.

The management of patients with hormone receptor (HR)-positive breast cancer continues to evolve, with phase 3 studies shedding light on the length of adjuvant anti-estrogen therapy, a novel treatment gaining approval, and new trials exploring combination strategies.

Metastatic breast cancer will strike 30% of all breast cancer survivors yet only 2% of funds go to research this deadly cancer.

Being offered the chance to be an inspiration isn't up to you. What you do with it afterwards, is.

Treatment with eribulin mesylate significantly extended overall survival (OS) compared with dacarbazine in patients with advanced soft tissue sarcoma, according to topline results from a phase 3 clinical trial.

Expanded access programs are run in conjunction with late-stage clinical trials so that promising investigational drugs can get into the hands of patients who stand a good chance of benefiting from them, and who have exhausted their other treatment options, including clinical trials.

Carl Harrington, who has lived with a rare cancer for the past nine years, offers advice to those newly diagnosed.

No matter how strong we are, the intense treatments, side effects, and emotional toll of cancer can push a person to her breaking point. If you are lucky, you have someone to help guide you through it.

A new study has shown that men with a history of testicular cancer have a higher incidence of developing prostate cancer, including intermediate or high-risk prostate cancer, compared with those without a history of testicular cancer.

Two new studies highlight the need for cancer survivors and their families to get guidance on healthy lifestyle changes and when the best time might be to integrate them.

Rintega (rindopepimut) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme (GBM) that test positive for the EGFR variant (EGFRvIII).

Recommendations for today to live a better, healthier tomorrow.

After nearly four years of cancer treatment, I thought I'd experienced all possible types of scanxiety. I was wrong.

The FDA has approved Farydak (panobinostat) in combination with Velcade (bortezomib) and dexamethasone for patients with multiple myeloma who receive prior treatment with Velcade and an immunomodulatory (IMiD) agent, based on results of the PANORAMA-1 trial.

Worrying and cancer go hand-in-hand. It's possible to take a step back from excessive worrying and give yourself a break.

The addition of Perjeta (pertuzumab) to Herceptin (trastuzumab) and docetaxel as a first-line therapy for metastatic HER2-positive breast cancer improved overall survival (OS) by nearly 16 months, according to findings from the phase 3 CLEOPATRA study.

One of the greatest challenges facing potential Lynch syndrome carriers is not having advice on the implications of a pending test and a subsequent positive result.

What does it take for patients with cancer who have exhausted their other medical options to gain access to late-stage investigational drugs?